Anxiety, Depression, and Women; Suicide Linked to ADHD

Prior to the COVID-19 pandemic, women were more likely to report symptoms of anxiety and depression versus men. However, Black and Hispanic women were less likely to receive treatment than white women. (ABC News)

But not surprisingly, stress and depressive symptoms have spiked during the pandemic, with one study linking media consumption to this rise. (ScienceDaily)

Dasotraline, a novel dopamine and norepinephrine reuptake inhibitor, was both safe and effective at reducing the number of binge-eating days per week after 12 weeks of treatment. Although the FDA accepted Sunovion’s new drug application for this treatment in July 2019, the company withdrew the application in May 2020 citing a need for more clinical studies. (Journal of Clinical Psychiatry)

A new app aimed at diagnosing autism may soon be a new arrow in pediatricians’ quiver. (Digital Trends)

In similar news, apps aiding in eating disorder recovery have boomed during the COVID-19 pandemic. (Wired)

Janssen is in pursuit of a court order to block Mylan’s generic version of its extended-release injectable schizophrenia treatment paliperidone (Invega Trinza). (Bloomberg Law)

States with a higher rate of firearm ownership had an increased risk of adolescent firearm suicide, as well as a near 7% increased risk in all-cause suicide. (Journal of the American Academy of Child & Adolescent Psychiatry)

Young adults with ADHD were more likely to attempt suicide than those without, a new study found. And this was particularly true among women. (Journal of Clinical Psychiatry)

  • author['full_name']

    Kristen Monaco is a staff writer, focusing on endocrinology, psychiatry, and dermatology news. Based out of the New York City office, she’s worked at the company for nearly five years.

Source Article